Sage Therapeutics (SAGE.US)盘初一度跌超13%，现涨超0.5%，报6.756美元。消息面上，Sage Therapeutics公司周二表示，由于在一项中期试验中没有达到主要目标，该公司将停止开发阿尔茨海默症药物。

Sage Therapeutics said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after ...

智通财经APP获悉，Sage Therapeutics ...

Sage Therapeutics, Inc. SAGE is focused on developing life-changing brain health medicines. In July, Sage Therapeutics and ...

Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said a mid-stage trial of a treatment for mild ...

Scotiabank的分析师指出，市场基本上已经预料到了这次试验的失败结果。然而，他们认为更重要的后果是，这为Sage Therapeutics进行重大重组铺平了道路。该公司强调，即使dalzanemdor在今年晚些时候即将公布结果的亨廷顿氏症2期DIMENSION研究中取得成功，由于该领域竞争日益激烈，仍然存在显著的开发风险。

周四,Raymond James恢复了对Sage Therapeutics (NASDAQ:SAGE)股票的覆盖,给予市场表现评级。该公司强调了对公司盈利能力和产品管线潜力的担忧。Raymond James的分析师指出,用于产后抑郁症 (PPD)的Zurzuvae的前景被认为相对温和。考虑到该药物的共享经济,Sage Therapeutics实现盈利的道路似乎充满挑战。

格隆汇10月8日｜Sage Therapeutics (SAGE.US)盘初一度跌超13%，现涨超0.5%，报6.756美元。消息面上，Sage ...

On Friday, SAGE Therapeutics Inc (SAGE) stock saw a modest uptick, ending the day at $6.59 which represents a slight increase of $0.22 or 3.45% from the prior close of $6.37. The stock opened at $6.33 ...

San Diego, California--(Newsfile Corp. - October 10, 2024) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sage Therapeutics, Inc. (NASDAQ: SAGE) securities between April ...

Sage Therapeutics is a sell due to failure of SAGE-324 in essential tremors and dalzanemdor's poor performance in Parkinson's ...

智通财经APP获悉，Sage Therapeutics (SAGE.US) 周二宣布阿尔茨海默病治疗药物dalzanemdor ...